A minisatellite polymorphism located in the 3Ј flanking region of the interleukin-6 (IL-6) gene was analysed in 192 Sardinian simplex families with multiple sclerosis (MS). By applying a high-resolution sizing approach, 9 alleles were identified. None of these were associated with in globo susceptibility to MS as shown by transmission disequilibrium testing. Analysis of clinically different groups showed that the A5 allele was associated with a benign (P = 0.007) but not with a malignant (P = 0.45) course of disease. In particular, the frequency of the A5/A5 genotype was significantly higher in patients with benign MS (P = 0.002). In addition, carriage of any of the larger alleles (A6 → A9) was associated with accelerated onset of disease (P = 0.025). Our results suggest that allelic variations in the IL-6 gene may predispose to alterations in the course and initial onset of MS. Genes and Immunity (2000) 1, 460-463.
Multiple sclerosis (MS) is considered to be a multifactorial demyelinating chronic inflammatory disease of the central nervous system (CNS), to which contribute both genetic and environmental factors. Several lines of research suggest that the cytokine interleukin-6 (IL-6) is involved in a variety of processes associated with CNS inflammation. However, unraveling the question as to whether this cytokine exerts a disease-promoting rather than limiting effect is complicated by potential differences in the influences of systemic or local IL-6 on onset and maintenance of CNS inflammation. In general, while elevated levels of CNS-associated IL-6 are thought to exert pro-inflammatory effects (eg, by upregulating expression of cell adhesion molecules), there are some indications that peripheral IL-6 may play a counteractive role. [1] [2] [3] [4] [5] [6] [7] Part of this beneficial effect has been attributed to the ability of this cytokine to induce protease inhibitors. 8 In the present study, we followed a genetic approach to understand whether IL-6 affects disease parameters in MS. A minisatellite polymorphism located in the 3Ј flanking region of the gene was typed by a high-resolution approach using the primers and reaction conditions described previously. 9 Heteroduplex formation is known to occur in IL-6 minisatellite amplification reactions, and this may compromise precise identification of alleles when non-denaturing PAGE is used (unpublished data, and personal communication by F Tschentscher and C Hardt). Separation of amplification products by means of denaturing PAGE on an automated DNA sequencer facilitated accurate sizing, and revealed the existence of more alleles than previously assumed on the basis of lowresolution non-denaturing electrophoresis (Table 1) . [9] [10] [11] In order to ensure that this effect was not due to the specific phylogenetic structure of the Sardinian population, 12 we typed also a representative sample of a continentalEuropean Caucasian (Swedish) population. This revealed that the sizes and number of IL-6 minisatellite alleles were identical in both populations, although Sardinian IL-6 allele frequencies deviated strongly from the Swedish ones, as expected (P Ͻ 0.0001). 12 Most remarkably, the F (Murray et al 10 ) or B4 (Bowcock et al 13 ) amplicons, which were in previous studies considered to represent a single allele, appeared to be composed actually of three different alleles (A1, 608 bp; A2, 615 bp and A3, 618 bp). The pooled frequencies of these three alleles in the Swedish population appeared to match well with the frequency of the F amplicon in the Scottish population, and that of the B4 amplicon in a non-specified Caucasian population (0.735, 0.75 and 0.84, respectively). 10, 13 Clinical and demographic characteristics of Sardinian MS patients have been published before.
14 All patients were ascertained to have clinically definite MS. 15 Trans- n refers to the numbers of chromosomes genotyped for the IL-6 minisatellite polymorphism. Combination of the alleles of 135 unrelated healthy control subjects and 384 nontransmitted parental alleles forming an affected family-based control population (AFBAC). 20 c Swedish healthy population sample consisting of 90 individuals.
d A8 was identified in two MS patients but not in healthy controls or AFBAC population. e Allele sizes are different because the primers used for amplification were distinct from those used in the present study and in the study by Bowcock et al. 13 mission disequilibrium of the IL-6 polymorphism was analysed in 192 Sardinian simplex MS families. Table 2 shows that no significant distortions in the global or individual patterns of IL-6 allele transmission from heterozygous parents to affected children were observed. This lack of effect was confirmed by AFBAC testing of association. Stratification of patients according to predisposing HLA type did not uncover any significant deviations. We further analysed the IL-6 gene polymorphism in MS patients, selected for a benign (EDSS р3.5 at 20 years from disease onset) or malignant (EDSS у6 at 5 years from disease onset) course of MS. This showed that the frequency of A5 was significantly higher in the group of patients with a benign course of MS (P = 0.007; P c = 0.05) than in the combined control/AFBAC population (A5 allele frequencies of 0.51 vs 0.35). No such difference in A5 frequency was seen in the subgroup of patients with a malignant course of MS (P = 0.45). As shown in Table 3 , the frequency of the homozygous genotype A5/A5 was significantly higher in MS patients with a benign course of disease (P = 0.002; P c = 0.02).
The ages at which clinical onset of disease occurred, were available for 155 patients. The median and average (±STDEV) values for age-at-onset in the whole group were 23 and 23.8 (±6.3), respectively. In order to test the hypothesis as to whether the IL-6 polymorphism may affect age-at-onset of disease, IL-6 allele frequencies were compared between subgroups with early (Ͻ20 years) and 
Grouped alleles with expected numbers р5 (A1, A7 and A8).
Genes and Immunity late onset of disease (Ͼ30 years). This analysis revealed that the pooled frequencies of the A6→A9 alleles were significantly higher in the group with early compared to late onset (0.21 vs 0.08; P = 0.05; P c = 0.10). As the cut-off values for delineation of onset in the former test were chosen arbitrarily, we sought to confirm a potential effect of the IL-6 polymorphism on age-at-onset by a more objective, non-parametric test, ie, the Wilcoxon rank sum test. This revealed a significant difference between age-atonset of carriers and non-carriers of any of the combined A6→A9 IL-6 alleles (P = 0.025; 40 carriers and 115 noncarriers). Of these 4 alleles, A6 and A9 constitute 96%. Performing the test with individual alleles yielded P values of 0.09 and 0.3 for differences in age-at-onset of A6 (non-)carriers and A9 (non-)carriers, respectively. This drop in significance level is explained by the fact that (i) patients with early onset of disease are proportionally equally distributed over A6 and A9 carriage groups, and (ii) patients with the genotype A6/A9 are rare (2/40). These results are therefore compatible with a model in which carriage of any of the IL-6 minisatellite alleles у658 bp accelerates onset of MS in Sardinian patients, either by direct effects, or as a consequence of linkage disequilibrium with a functional polymorphism in the same or a nearby gene. Nevertheless, it should be noted that the strength of the association between IL-6 and early onset of disease was inferior to that with clinical course of disease. e No differences (P = 0.65) were seen between the A5/A5 genotype frequencies of controls (n = 135; A5/A5 genotype frequency of 0.12) and the AFBAC population (n = 192; A5/A5 genotype frequency of 0.13).
The polymorphism studied here is located in the 3Ј flanking region of the interleukin-6 gene. 13 Association of the IL-6 minisatellite polymorphism with systemic lupus erythematosus (SLE) has been reported recently. 16 Here, in both Caucasian and African-American populations, an 828 bp IL-6 allele was found to be significantly underrepresented in SLE patients. 16 Taking into account the different primers used for amplification of the IL-6 minisatellite in the present and former study, careful examination shows that the 828 bp allele 16 corresponds to the 650 bp A5 allele of the present study. In a study on German Caucasian patients with Alzheimer's disease (AD), IL-6 minisatellite allele A5 (allele C according to the classification of Murray et al 10 ) was found to be associated with delayed onset of disease and reduced disease risk. 11 We demonstrate here that the same allele is associated with a benign course of MS. Notwithstanding their highly divergent etiologies, MS, SLE and AD share the characteristic of being conditions in which dysregulation of cytokine responses may aggravate disease. In whichever of these conditions, the A5 allele seems to exert similar effects-in that it decreases the risks for SLE and AD, and weakens the clinical course of MS.
A functional G/C single nucleotide polymorphism (SNP) has been identified at position −174 in the 5Ј flanking region of the IL-6 gene. Of this SNP, only the G allele was found to be inducible by IL-1 or LPS. 17 The noninducible CC genotype was significantly underrepresented in children with early (р5 year) onset of systemiconset juvenile chronic arthritis (S-JCA). 17 Remarkably, this SNP was found not to be associated with SLE 16 or AD. 18 The A5 allele is associated with a low IL-6 producer phenotype. 16 Taken together, these findings are suggestive for a direct effect of the 3Ј IL-6 minisatellite on transcriptional control of the gene.
There is a growing consensus that the combined epistatic effects of multiple minor genes may determine both susceptibility and disease heterogeneity of MS. Because of their effects, cytokine genes are obvious candidates. The results presented in the current and in a previous study suggest that dysregulatory mutations in the IL-6 and IFN-␥ cytokine genes 19 might modify the course and risk of MS in Sardinia.
